SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol 2011; 23: 4118.
  • 2
    Rose CD, Wouters CH, Meiorin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006; 54: 333744.
  • 3
    Janssen CE, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, Cimaz R, et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol 2012; 129: 107684.
  • 4
    Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 1920.
  • 5
    Fink CW, Cimaz R. Early onset sarcoidosis: not a benign disease. J Rheumatol 1997; 24: 1747.
  • 6
    Raiji VR, Miller MM, Jung LK. Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 2011; 15: 2057.
  • 7
    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 241625.
  • 8
    Falcini F, Battini ML, Ceruso M, Cimaz R. A 4-year-old with a rash. Lancet 1999; 354: 40.
  • 9
    Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 15064.
  • 10
    Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 74754.
  • 11
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 9981006.
  • 12
    Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, et al. NOD2 gene–associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56: 380513.
  • 13
    Pan Q, Mathison J, Fearns C, Kravchenko VV, Da Silva Correia J, Hoffman HM, et al. MDP-induced interleukin-1β processing requires Nod2 and CIAS1/NALP3. J Leukoc Biol 2007; 82: 17783.
  • 14
    Martin TM, Zhang Z, Kurz P, Rose CD, Chen H, Lu H, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009; 60: 6118.
  • 15
    Masumoto J, Yamazaki T, Ohta K, Nakayama J, Agematsu K. Interleukin-1β suppression in Blau syndrome: comment on the article by Martin et al [letter]. Arthritis Rheum 2009; 60: 25445.
  • 16
    Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 147986.
  • 17
    Foley KP, Wang L, Cooper D, Magid-Slav M, Lipshutz D, Connor J, et al. Identification of Blau syndrome disease signatures. Pediatr Rheumatol 2011; 9 Suppl 1: O25.